The National Institute of Allergy and Infectious Diseases (NIAID) has developed a monoclonal antibody (mAb) called mAb CIS43LS targeting malaria. They are now enrolling healthy adult volunteers in a Phase I clinical trial testing the safety and effectiveness of the...